Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

B-type natriuretic peptide in heart failure.

Gordon W Moe1

  • 1St. Michael's Hospital, Toronto, Ontario, Canada. moeg@smh.toronto.on.ca

Current Opinion in Cardiology
|April 8, 2006
PubMed
Summary

B-type natriuretic peptide (BNP) and NT-proBNP are valuable biomarkers for diagnosing heart failure and predicting patient outcomes. BNP testing aids in management, while nesiritide shows promise for acute decompensated heart failure.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidemiology of COVID-19 and Its Cardiac and Neurologic Complications Among Chinese and South Asians in Ontario: Waves 1, 2, and 3.

CJC open·2022
Same author

Outcomes of Transcatheter Edge-to-Edge Repair, Surgical and Medical Therapy in Combined Mitral and Tricuspid Regurgitation.

JACC. Cardiovascular interventions·2022
Same author

Awareness of Warning Symptoms of Heart Disease and Stroke: Results of a Follow-up Study of the Chinese Canadian Cardiovascular Health Project.

CJC open·2021
Same author

COVID-19 and its Cardiac and Neurological Complications among Ontario Visible Minorities.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2021
Same author

Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure.

JACC. Heart failure·2021
Same author

CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction.

The Canadian journal of cardiology·2021

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Research

Background:

  • Heart failure is a prevalent condition with high mortality and morbidity.
  • Conventional diagnostic tools can be insufficient for accurate heart failure diagnosis.
  • Cardiac natriuretic peptides, including BNP, are established biomarkers in cardiovascular disease.

Purpose of the Study:

  • To review recent literature on the role of B-type natriuretic peptide (BNP) in heart failure.
  • To highlight the diagnostic and prognostic utility of BNP and NT-proBNP.
  • To discuss the therapeutic implications of BNP and nesiritide in heart failure management.

Main Methods:

  • Literature review of recent studies on BNP and NT-proBNP in heart failure.
  • Analysis of data on the diagnostic accuracy and prognostic value of these biomarkers.
  • Evaluation of preliminary findings on BNP-guided therapy and exogenous BNP (nesiritide).

Main Results:

  • Plasma BNP and NT-proBNP levels are closely associated with heart failure diagnosis.
  • These biomarkers independently predict mortality and adverse heart failure events.
  • Preliminary data suggest BNP/NT-proBNP levels may optimize heart failure management.
  • Nesiritide improves hemodynamics and dyspnea in acute decompensated heart failure.

Conclusions:

  • BNP or NT-proBNP testing is highly useful for diagnosing and predicting prognosis in heart failure.
  • Nesiritide shows potential for managing acute decompensated heart failure.
  • Ongoing large-scale trials will further clarify the impact of BNP-guided therapy and exogenous BNP on clinical outcomes.

Related Experiment Videos